文献速递炎症性肠病消化道肿瘤与早癌

免疫抑制治疗下炎症性肠病患者基底细胞癌重复发生风险

Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

本研究为回顾性队列研究,纳入54,919例在退伍军人事务医疗系统随访的炎症性肠病患者,识别其中发生基底细胞癌者,按用药分组分析重复发生基底细胞癌的风险。结果显示,与单用5-氨基水杨酸相比,仅活动性硫嘌呤使用与重复基底细胞癌风险升高相关(aHR 1.65,95%CI 1.24-2.19,P=0.0005),其他暴露类别未见风险升高。

要点

  • 在IBD发生基底细胞癌的患者中,持续使用硫嘌呤与重复基底细胞癌风险升高相关。
  • 与单用5-ASA相比,仅活动性硫嘌呤使用的aHR为1.65(95%CI 1.24-2.19)。
  • 其他用药类别(既往硫嘌呤、抗TNF等)未显示重复基底细胞癌风险显著升高。

核心结论

  • 在发生基底细胞癌时正在使用硫嘌呤并继续使用的IBD患者中,重复基底细胞癌发生风险升高。

研究设计与样本

  • 回顾性队列研究,纳入54,919例在退伍军人事务医疗系统随访的炎症性肠病患者。
  • 识别IBD诊断后发生基底细胞癌的患者,按IBD用药分为六类暴露组。
  • 结局为基底细胞癌重复发生,采用调整和未调整的风险比(95%CI)估计风险。

主要发现

  • 共518例患者在IBD诊断后发生基底细胞癌。
  • 每100人年重复基底细胞癌发生数:单用5-ASA 12.8,活动性硫嘌呤34.5,既往硫嘌呤且无抗TNF 19.3,既往硫嘌呤后抗TNF 25.4,仅抗TNF 17.8,活动性抗TNF联合硫嘌呤22.4。
  • 与单用5-ASA相比,仅活动性硫嘌呤使用与重复基底细胞癌风险升高相关(aHR 1.65,95%CI 1.24-2.19;P=0.0005)。
  • 其他暴露类别未显示重复基底细胞癌风险显著升高。

关键数值与推荐

  • 活动性硫嘌呤使用对比单用5-ASA:aHR 1.65(95%CI 1.24-2.19;P=0.0005)。
  • 每100人年重复基底细胞癌发生数:单用5-ASA 12.8,活动性硫嘌呤34.5,既往硫嘌呤且无抗TNF 19.3,既往硫嘌呤后抗TNF 25.4,仅抗TNF 17.8,活动性抗TNF联合硫嘌呤22.4。

临床怎么用

  • 对使用硫嘌呤的IBD患者,尤其既往发生基底细胞癌者,应关注皮肤监测和重复基底细胞癌风险。
  • 临床决策时可参考不同免疫抑制方案下重复基底细胞癌的发生率数据。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are limited data on repeated basal cell cancer (BCC) occurrences among patients with inflammatory bowel disease (IBD), especially the impact of continuing immunosuppressive medications. METHODS: We conducted a retrospective cohort study of 54,919 patients with IBD followed in the Veterans Affairs Healthcare System. We identified patients who had an incident BCC after their IBD diagnosis. We defined patients' exposure based on their IBD medications use as follows: (i) only aminosalicylate (5-ASA) use, (ii) only active thiopurine (TP) use, (iii) past TP use (discontinued >6 months ago) and no antitumor necrosis factor (TNF) use, (iv) anti-TNF use after previous TP use, (v) only anti-TNF use, and (vi) active anti-TNF and TP use. The outcome of interest was the repeated occurrence of BCC. Adjusted and unadjusted hazard ratios with 95% confidence intervals were used to estimate the risk of repeated BCC occurrence. RESULTS: A total of 518 patients developed BCC after their IBD diagnosis. The numbers of repeated BCC occurrences per 100 person-years were 12.8 (5-ASA use only), 34.5 (active TP use), 19.3 (past TP use and no anti-TNF use), 25.4 (anti-TNF use after previous TP use), 17.8 (only anti-TNF use), and 22.4 (active anti-TNF and TP use). Compared with 5-ASA use alone, only active TP use was associated with an increased risk for repeated BCC occurrence (adjusted hazard ratio 1.65, 95% confidence interval 1.24-2.19; P = 0.0005). However, the increased risk was no longer present for other exposure categories. DISCUSSION: Among IBD patients who developed an incident BCC while taking a TP and continued it, there was an increased risk of repeated BCC occurrences.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Khan N, Patel D, Trivedi C, et al. Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications. Am J Gastroenterol. 2020. PMID: 32453047. doi:10.14309/ajg.0000000000000679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。